Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A1 | P22736 | 1/20 | 0.72 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.72 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.72 |
| ▸ | CDC25B | P30305 | 2/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | GMNN | O75496 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.51 |
| ▸ | BLM | P54132 | 2/20 | 0.51 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.51 |
| ▸ | CMKLR1 | Q99788 | 2/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Naphthoic Acid SCHEMBL27837568 | 0.87 | NR4A1 (0.81) | NR4A1NR4A2NR4A3CDC25BTDP1 | |
| Naphthoic Acid SCHEMBL8715113 | 0.87 | NR4A1 (0.95) | NR4A1NR4A2NR4A3CDC25BTDP1 | |
| Naphthoic Acid SCHEMBL28570317 | 0.86 | NR4A1 (0.72) | NR4A1NR4A2NR4A3CDC25BTDP1 | |
| Naphthoic Acid SCHEMBL29095974 | 0.86 | NR4A1 (0.78) | NR4A1NR4A2NR4A3CDC25BTDP1 | |
| Phthalic Acid SCHEMBL30717997 | 0.85 | ALDH1A1 (0.61) | NR4A1NR4A2NR4A3CDC25BTDP1 | |
| Naphthoic Acid SCHEMBL30401620 | 0.85 | NR4A1 (0.91) | NR4A1NR4A2NR4A3CDC25BTDP1 | |
| Phthalic Acid SCHEMBL8155 | 0.85 | ALDH1A1 (0.61) | NR4A1NR4A2NR4A3CDC25BTDP1 | |
| Naphthoic Acid SCHEMBL29352220 | 0.85 | NR4A1 (1.00) | NR4A1NR4A2NR4A3CDC25BTDP1 | |
| Naphthoic Acid SCHEMBL30233567 | 0.85 | NR4A1 (1.00) | NR4A1NR4A2NR4A3CDC25BTDP1 | |
| Naphthoic Acid SCHEMBL17258 | 0.85 | NR4A1 (1.00) | NR4A1NR4A2NR4A3CDC25BTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2006002031-A1 | SUSTAINED RELEASE DOSAGE FORMS | ANDRX CORPORATION (US) | 2006-01-05 | — | — | WO | claimed |
| US-20050276849-A1 | Sustained release dosage forms | ANDRX CORPORATION | 2005-12-15 | — | — | US | claimed |
| US-20090196924-A1 | CONTROLLED-RELEASE LAMOTRIGINE FORMULATIONS | DR. REDDY'S LABORATORIES LIMITED (IN) | 2009-08-06 | — | — | US | disclosed |
| CN-100376634-C | Cassade polymer composition with trigger response | ROHM & HAAS (US) | 2008-03-26 | — | — | CN | disclosed |
| CN-100338136-C | Trigger corresponding compsn. | ROHM & HAAS (US) | 2007-09-19 | — | — | CN | disclosed |
| CN-1320077-C | Trigger response compositioin | ROHM & HAAS (US) | 2007-06-06 | — | — | CN | disclosed |
| WO-2006002031-A1 | SUSTAINED RELEASE DOSAGE FORMS | ANDRX CORPORATION (US) | 2006-01-05 | — | — | WO | disclosed |
| US-20050276849-A1 | Sustained release dosage forms | ANDRX CORPORATION | 2005-12-15 | — | — | US | disclosed |
| CN-1510085-A | Cassade polymer composition with trigger response | 罗姆和哈斯公司 | 2004-07-07 | — | — | CN | disclosed |
| CN-1480488-A | Trigger corresponding compsn. | ��������ķ������ | 2004-03-10 | — | — | CN | disclosed |
| CN-1477173-A | Trigger response compositioin | 罗姆和哈斯公司 | 2004-02-25 | — | — | CN | disclosed |
| US-4256108-A | Microporous-semipermeable laminated osmotic system | ALZA CORPORATION (US) | 1981-03-17 | — | — | US | disclosed |
| US-4200098-A | Osmotic system with distribution zone for dispensing beneficial agent | ALZA CORPORATION (US) | 1980-04-29 | — | — | US | disclosed |
| US-4160452-A | Osmotic system having laminated wall comprising semipermeable lamina and microporous lamina | ALZA CORPORATION (US) | 1979-07-10 | — | — | US | disclosed |
| US-4160020-A | CELLULOSE ESTERS, CELLULOSE ETHERS | ALZA CORPORATION (US) | 1979-07-03 | — | — | US | disclosed |
| US-4116241-A | FOR CONTROLLED ORAL ADMINISTRATION OF DRUG | ALZA CORPORATION (US) | 1978-09-26 | — | — | US | disclosed |
| US-4077407-A | POLYSACCHARIDES | ALZA CORPORATION (US) | 1978-03-07 | — | — | US | disclosed |
| US-4058122-A | Osmotic system with laminated wall formed of different materials | ALZA CORPORATION (US) | 1977-11-15 | — | — | US | disclosed |
| US-4014334-A | Laminated osmotic system for dispensing beneficial agent | ALZA CORPORATION (US) | 1977-03-29 | — | — | US | disclosed |
| US-4008719-A | Osmotic system having laminar arrangement for programming delivery of active agent | ALZA CORPORATION (US) | 1977-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090196924-A1 | CONTROLLED-RELEASE LAMOTRIGINE FORMULATIONS | LAMTOR3, CACNA1F, CACNA1G | NR4A1 3680/4885NR4A2 3423/4885NR4A3 3083/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.